Malignancy Risk Varies With Treatment in Systemic Necrotizing Vasculitis Malignancy Risk Varies With Treatment in Systemic Necrotizing Vasculitis

The risk of malignancy in patients with systemic necrotizing vasculitis (SNV) varies according to the treatment received, according to an analysis of five randomized controlled trials.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Rheumatology News Source Type: news